‘What Doesn't Kill Us' Review: Freeze Your Enthusiasm
The book became a bestseller and helped transform Mr. Hof into a celebrity, popularizing his training methods—particularly cold plunges, which involve immersing oneself in frigid water for a few minutes at a time. Capitalizing on the sales of 'What Doesn't Kill Us,' in 2020 Mr. Hof wrote his own book, which has been translated into multiple languages.
Never mind that Mr. Carney's book came with an ominous full-page disclaimer, warning that the practices described in the book 'are inherently dangerous and could result in grave harm or death.' It's tempting to dismiss the foreboding tone as a publicity stunt to juice sales. But since then, Mr. Carney tells us in a new edition of his book, he has 'collected more than thirty reports of people who have drowned while following Hof's example by practicing his breathwork techniques in water.'
In a 15-page afterword to the new edition, Mr. Carney tells us that Mr. Hof's representatives respond by insisting there are warnings—for instance, in the descriptions attached to Mr. Hof's demonstration videos on YouTube—against using his breathing techniques 'in a swimming pool, before going underwater, beneath the shower, or piloting any vehicle.' Mr. Carney isn't convinced, citing a video marketed by Mr. Hof in which he contradicts his own guidance. 'At the very least, the juxtaposition between the written warning and Hof's own words is confusing. At worst, it's a dramatic acknowledgment of the sort of negligence that could get someone killed.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
Fully integrated AI decision support tool flags B scans that may require further review, supporting more confident decision making and more efficient patient care. JENA, Germany, Aug. 21, 2025 /PRNewswire/ -- ZEISS Medical Technology today announced CE mark approval for CIRRUS® PathFinder™, an innovative clinical support tool with artificial intelligence (AI) fully integrated to enable more confident decision-making and accelerate a clinician's workflow with OCT interpretation assistance. ZEISS CIRRUS PathFinder1 uses proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans as a licensed element of a new CIRRUS software release, that also provides AI-enhanced OCTA image quality and multi-layer segmentation, helping to improve a practice's workflow efficiency and patient care. "At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience." "ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder." New research shows that physicians who leverage AI algorithms can be more effective than a practitioner alone. ZEISS CIRRUS with PathFinder delivers high-speed image capture with HD imaging detail 2, a wide field of view, and AI decision support, helping clinicians make more informed and efficient decisions. "With PathFinder AI Decision Support, our game-changing technology identifies OCT B-scans that may require additional review, raising our advanced diagnostic portfolio to a new level of patient care support," says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology. Improved clinical decision support – Without requiring export and data analysis from third-party platforms, CIRRUS PathFinder's fully integrated AI decision support algorithm interprets data within the clinician's current workflow, allowing for the assessment of many hundreds of scans at once, in real time, upleveling the value of a clinician's time. During image acquisition, this AI-guided workflow tool flags areas that may require more detailed imaging and, during review, allows the user to focus on what matters – improving patient care. Improved OCTA image quality – New CIRRUS operating software provides AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further enhances the user's diagnostic capability for even more efficient decision making. Enhanced connectivity and security – New cybersecurity features are designed to meet ever-evolving compliance and security needs. Additionally, the ZEISS CIRRUS platform ensures the seamless review of legacy OCT data combined with other diagnostic modalities to further enhance patient care. CIRRUS® PathFinder™ is available via license within the new CIRRUS software update, which includes an expanded Reference Database (RDB) that is triple the size of the previous RDB, cybersecurity enhancements, multi-layer segmentation, and improved OCTA visualization. The software update is available in select markets. For more information about CIRRUS PathFinder, go here. 1 ZEISS PathFinder works on all current ZEISS CIRRUS devices: 500, 5000, 6000, however RDB2 is for ZEISS CIRRUS 6000 data only.2 As it relates to the ZEISS CIRRUS 6000 only. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support. Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: Contact for the pressFrank SmithHead of Global CommunicationsZEISS OphthalmologyCarl Zeiss Meditec +49 3641 220 331Mail: Brief Profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of €2,066.1m in fiscal year 2023/24 (to 30 September). The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG's shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. For further information visit: SOURCE Carl Zeiss Meditec AG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
an hour ago
- Medscape
How Can Europe Reduce Heat Deaths Amid Rising Temperatures?
The Pan-European Commission on Climate and Health has released an open letter urging action against the escalating health crisis in Europe and Central Asia that is stemming from climate change. Europe is the fastest-warming region in the world, warming up twice as fast as the global average. While 2024 was the hottest year on record for continental Europe, 2025 is already on its way to surpassing it. T emperatures rose above 30 ˚C for an unprecedented 22 days in Scandinavia, while Spain and Portugal experienced heat exceeding 46 ˚C in June. Such temperature rises have had a deleterious impact on health; data show that heat-related mortality has increased by more than 30% in the last two decades in Europe. This trend is showing no signs of slowing down. An analysis by Imperial College London , London, England, reported that 1500 of the 2300 heat deaths in the week between June 23 and July 2, 2025, were a direct result of climate change-related temperature rises of 1-4 °C. Excess heat can exacerbate underlying health issues like c ardiovascular disease, diabetes, mental health conditions, and asthma , and increase the risk for accidents and the transmission of some infectious diseases. Older people, young children, and pregnant women are at particular risk. 'In the summer of 2022, 60,000-70,000 [people] died in Europe because of heat,' Julie Berckmans, PhD, European Environment Agency (EEA) climate risk and adaptation expert, told Medscape Medical News . 'In 2023, it was 47,000 people. These numbers could increase substantially in the coming decades. To avoid this, effective actions have to be implemented to protect vulnerable people.' A man cools off at a fountain in Square at the Vatican on August 13, 2025. Italy faced extreme heat in August as temperatures above 40 °C gripped the country. Heat-Health Actions Plans (HHAPs) In their letter, the Pan-European Commission on Climate and Health highlighted the need for HHAPs to save lives and prevent further climate decline. HHAPs provide a framework for reducing the health impacts of extreme heat. They focus on eight core elements: a governing structure for heat-health action, warning systems, care for vulnerable populations, heat-health communications planning, health system resilience, reduced heat exposure, surveillance, and a process for review and improvement, Vladimir Kendrovski, MD, PhD, World Health Organization (WHO)/Europe technical officer for climate change and health, told Medscape Medical News . At present, 21 of the 38 countries belonging to the EEA network, Eionet, have HHAPs in place. While this is encouraging, said Kendrovski, accelerating their development and implementation across Europe remains a 'critical priority.' Many countries began to implement HHAPs in response to the 2003 heatwave — the hottest period in continental Europe since at least 1540, claiming more than 70,000 lives. France and Italy , for example, saw significant declines in heat-related deaths after implementing preventative measures like warning system s, information campaigns for the public , and a ir conditioning equipment and emergency protocols for health centers and retirement homes. Some measures, however, are more widespread than others. Kendrovski noted that a survey of member states in the region found that long-term urban planning and real-time surveillance, monitoring, and evaluation are still lacking. Andreas Hoy, PhD, senior expert and climate scientist at the Stockholm Environment Institute Tallinn, in Tallinn, Estonia, noted that the technical components of early meteorological warning systems have been significantly updated in recent years, thus enabling better warning systems. However, he added, an absence of formal standards has led to wide variations in HHAP structures, objectives, and execution. 'This inconsistency often produces fragmented efforts and leaves major gaps in funding, vulnerability assessments, and long-term resilience planning,' he said. Lateral Public Health While improved infrastructure is important, community engagement is key toward ensuring it is used properly to ultimately reduce deaths, Jan Semenza, PhD, project manager at the Department of Epidemiology and Global Health at Umeå University, Umeå, Sweden, told Medscape Medical News . Toward this end, he recommends a 'lateral' as opposed to 'vertical' approach to public health : rather than eliminating one health threat at a time, such as polio through vaccination campaigns, lateral approaches enhance community cohesion for a more self-organized and thus agile collective response to disasters, including heatwaves. Measures may include community-based surveillance, health education, and projects like establishing urban gardens to cool air through transpiration or painting roofs green to reduce rooftop temperatures. 'One thing we found from our research in Chicago,' said Semenza, 'is that people who have social connections, participate in church communities, or even have a pet that allows you to go outside and connect with people — these are the ones that are more likely to survive. If you're isolated, nobody looks after you.' Semenza added that urban planning should also be taken into account and recommended the creation of more green spaces to offset heating from cement and concrete. More Solutions Hoy noted that while long-term solutions aimed at reducing greenhouse gas emissions to prevent further heating are necessary, public awareness campaigns are still needed in the short-term to help people stay safe during heatwaves. 'Providing clear and simple guidance on how to stay safe during a heatwave can save lives: such as staying hydrated, seeking shade, and looking out for elderly neighbors, friends, and family members,' he told Medscape Medical News . In terms of immediate solutions, Ilona M. Otto, PhD, deputy director at the Wegener Center for Climate and Global Change at the University of Graz, Graz, Austria, recommends using public spaces and buildings, such as libraries, as cooling centers, in addition to providing access to drinking stations, improved insulation, and assistance to vulnerable people living alone. Regulations for working conditions may also need to be adjusted, she said, to ensure that those working in difficult conditions can take more breaks, have more access to water, and perhaps stop working at the hottest times of the day. Healthcare professionals also have a key role in implementing HHAPs, Rachel Lowe, PhD, Catalan Institution for Research and Advanced Studies Research Professor at the Barcelona Supercomputing Center, told Medscape Medical News. 'Health professionals can detect and treat heat-sensitive and climate-related illnesses early and educate patients on prevention. They also play a key role in public awareness, surveillance, and advocating for greener, more resilient health systems that can withstand climate pressures and reduce the carbon footprint of the health sector,' she said. The WHO Regional Office for Europe is currently developing new guidance for HHAPs, which is expected to be published in Spring 2026. Berckmans, Kendrovski, Lowe, and Semenza reported no relevant financial relationships. Otto noted that a part of her work has been carried out within the HIGH Horizons project , funded by the European Union's Horizon Research and Innovation programme. Their project partner, London School of Hygiene & Tropical Medicine, is funded by UK Research & Innovation. Hoy declined to disclose any relevant financial relationships.
Wall Street Journal
2 hours ago
- Wall Street Journal
Spurred by AI, Healthtech Venture Funding Rebounds
Growing acceptance of artificial intelligence in medicine is powering a revival of venture-capital investment in medical software and other healthcare technologies. U.S. and European healthtech startups raised $7.9 billion in venture capital in the first half, putting this year on pace to be the best funding year for the sector since 2022, when companies collected $16.3 billion for the full year, according to Silicon Valley Bank, a division of First Citizens Bank.
